Natural course of metastatic castration‐resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone‐sensitive setting
Authors: Gebrael Georges , Hage Chehade Chadi , Sayegh Nicolas , Tripathi Nishita , Chigarira Beverly , Goel Divyam , Nordblad Blake , McFarland Taylor R. , Narang Arshit , Srivastava Ayana , Tandar Clara , Dal Emre , Jo Yeonjung , Galarza Fortuna Gliceida , Mathew Thomas Vinay , Sahu Kamal K. , Li Haoran , Maughan Benjamin L. , Swami Umang , Agarwal Neeraj 
Published: April 2024

Background

Androgen deprivation therapy (ADT) intensification (ADTi) (i.e., ADT with androgen receptor pathway inhibitor or docetaxel, or both) has significantly improved survival outcomes of patients with metastatic hormone‐sensitive prostate cancer (mHSPC). However, the impact of prior ADTi in the mHSPC setting on the disease presentation and survival outcomes in metastatic castration‐resistant prostate cancer (mCRPC) is not well characterized. In this study, our objective was to compare the disease characteristics and survival outcomes of patients with new mCRPC with respect to receipt of intensified or nonintensified ADT in the mHSPC setting.

Methods

In this institutional review board‐approved retrospective study, eligibility criteria were as follows: patients diagnosed with mCRPC, treated with an approved first‐line mCRPC therapy, and who received either intensified or nonintensified ADT in the mHSPC setting. Progression‐free survival (PFS) was defined from the start of first‐line therapy for mCRPC to progression per Prostate Cancer Working Group 2 criteria or death, and overall survival (OS) was defined from the start of first‐line therapy for mCRPC to death or censored at the last follow‐up. A multivariable analysis using the Cox proportional hazards model was used, adjusting for potential confounders.

Results

Patients (n = 387) treated between March 20, 2008, and August 18, 2022, were eligible and included: 283 received nonintensified ADT, whereas 104 were treated with ADTi. At mCRPC diagnosis, patients in the ADTi group were significantly younger, had more visceral metastasis, lower baseline prostate‐specific antigen (all p < 0.01), and lower hemoglobin (p = 0.027). Furthermore, they had significantly shorter PFS (median 4.8 vs. 8.4 months, adjusted hazard ratio [HR]: 1.46, 95% confidence interval [95% CI]: 1.07–2, p = 0.017) and OS (median 21.3 vs. 33.1 months, adjusted HR: 1.53, 95% CI: 1.06–2.21, p = 0.022) compared to patients in the nonintensified ADT group.

Conclusion

Patients treated with ADTi in the mHSPC setting and experiencing disease progression to mCRPC had more aggressive disease features of mCRPC (characterized by a higher number of poor prognostic factors at mCRPC presentation). They also had shorter PFS on first‐line mCRPC treatment and shorter OS after the onset of mCRPC compared to those not receiving ADTi in the mHSPC setting. Upon external validation, these findings may impact patient counseling, prognostication, treatment selection, and design of future clinical trials in the mCRPC setting. There remains an unmet need to develop novel life‐prolonging therapies with new mechanisms of action to improve mCRPC prognosis in the current era.